Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer

被引：0
|
作者：
Bilgin, Burak [1 ]
Sendur, Mehmet A. N. [1 ]
Hizal, Mutlu [1 ]
Akinci, Muhammed Bulent [1 ]
Dede, Didem Sener [1 ]
Yalcin, Bulent [1 ]
机构：
[1] Yildirim Beyazit Univ, Dept Med Oncol, Ankara, Turkey
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 02期
关键词：
FULVESTRANT; 500; MG; DOUBLE-BLIND; THERAPY; PALBOCICLIB;
D O I：
10.2217/fon-2018-0086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：105 / 107
页数：3
相关论文
共 50 条
  • [21] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [22] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Zheng, Hongjuan
    Ge, Chenyang
    Lin, Haiping
    Wu, Lunpo
    Wang, Qinghua
    Zhou, Shishi
    Tang, Wanfen
    Zhang, Xia
    Jin, Xiayun
    Xu, Xifeng
    Hong, Zhongwu
    Fu, Jianfei
    Du, Jinlin
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1145 - 1153
  • [23] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Hongjuan Zheng
    Chenyang Ge
    Haiping Lin
    Lunpo Wu
    Qinghua Wang
    Shishi Zhou
    Wanfen Tang
    Xia Zhang
    Xiayun Jin
    Xifeng Xu
    Zhongwu Hong
    Jianfei Fu
    Jinlin Du
    International Journal of Clinical Oncology, 2022, 27 : 1145 - 1153
  • [24] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Rozenblit, Mariya
    Mun, Sophia
    Soulos, Pamela
    Adelson, Kerin
    Pusztai, Lajos
    Mougalian, Sarah
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [25] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [26] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Gligorov, Joseph
    Lotz, Jean-Pierre
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (Suppl 1) : 53 - 66
  • [27] FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
    Shah, Anand
    Bloomquist, Erik
    Tang, Shenghui
    Fu, Wentao
    Bi, Youwei
    Liu, Qi
    Yu, Jingyu
    Zhao, Ping
    Palmby, Todd R.
    Goldberg, Kirsten B.
    Chang, C. J. George
    Patel, Paresma
    Alebachew, Elleni
    Tilley, Amy
    Pierce, William F.
    Ibrahim, Amna
    Blumenthal, Gideon M.
    Sridhara, Rajeshwari
    Beaver, Julia A.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2018, 24 (13) : 2999 - 3004
  • [28] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Joseph Gligorov
    Jean-Pierre Lotz
    Breast Cancer Research and Treatment, 2008, 112 : 53 - 66
  • [29] Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Usami, Eiseki
    Noguchi, Yoshihiro
    Yoshimura, Tomoaki
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (06) : 1258 - 1266
  • [30] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Mariya Rozenblit
    Sophia Mun
    Pamela Soulos
    Kerin Adelson
    Lajos Pusztai
    Sarah Mougalian
    Breast Cancer Research, 23
12345